H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 14:51
Regulatory Filings
English 96.8 KB
2025-11-14 12:45
M&A Activity
English 25.3 KB
2025-11-14 12:45
Regulatory Filings
English 96.8 KB
2025-11-11 15:22
Regulatory Filings
English 116.4 KB
2025-11-11 15:22
Earnings Release
English 24.6 KB
2025-09-20 08:00
Regulatory Filings
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim / Quarterly Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for H. Lundbeck A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BELITE BIO, INC Logo
Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.
United States of America
BLTE
Benitec Biopharma Inc. Logo
Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Develops innovative and accessible cancer treatments for patients worldwide.
United States of America
ONC
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway
BGBIO
BeyondSpring Inc. Logo
Develops innovative immuno-oncology cancer therapies, including a 'pipeline in a drug' asset.
United States of America
BYSI
BGM Group Ltd. Logo
A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.
South Korea
238200

Talk to a Data Expert

Have a question? We'll get back to you promptly.